Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F10%3A00008797" target="_blank" >RIV/00023736:_____/10:00008797 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

Popis výsledku v původním jazyce

Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies.

Název v anglickém jazyce

Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

Popis výsledku anglicky

Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/LC06044" target="_blank" >LC06044: Centrum experimentální hematologie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Molecular Pharmacology

ISSN

1874-4672

e-ISSN

—

Svazek periodika

3

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

25

Strana od-do

98-122

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—